In line with the immunogenicity of ARID1A mutation, a more recent study in 417 colorectal cancer patients demonstrated that ARID1A mutation may define an immunologically active subgroup in patients with microsatellite stable (MSS) tumors [64]. Here, ARID1A is linked to colorectal cancer.